Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral, Idiopathic Parkinson's Disease (SUNRISE-PD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03720418

Recruitment Status : Terminated (As a result of termination of development of OXB-102-01, it is no longer possible for Sio to either commence or to continue any related clinical trials.)

First Posted : October 25, 2018

Last Update Posted : May 3, 2022

Sponsor:

Information provided by (Responsible Party):

Sio Gene Therapies

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Terminated
Actual Primary Completion Date :	April 12, 2022
Actual Study Completion Date :	April 12, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

McFarthing K, Prakash N, Simuni T. CLINICAL TRIAL HIGHLIGHTS: 1. GENE THERAPY FOR PARKINSON'S, 2. PHASE 3 STUDY IN FOCUS - INTEC PHARMA'S ACCORDION PILL, 3. CLINICAL TRIALS RESOURCES. J Parkinsons Dis. 2019;9(2):251-264. doi: 10.3233/JPD-199001.

To Top